MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

MAIA Biotechnology (NYSE American: MAIA) announced that the CEO and certain directors purchased approximately 182,445 shares of MAIA common stock in open-market trades between November 21 and 28, 2025 at an average price of $1.06 per share.

Rhea-AI Summary

MAIA Biotechnology (NYSE American: MAIA) announced that the CEO and certain directors purchased approximately 182,445 shares of MAIA common stock in open-market trades between November 21 and 28, 2025 at an average price of $1.06 per share. Vlad Vitoc, chairman and CEO, purchased 94,300 shares at an average of $1.08, while directors Cristian Luput and Stan V. Smith purchased a combined 88,145 shares at an average of $1.04.

The company highlighted clinical progress for ateganosine in its Phase 2 THIO-101 trial, reporting a 38% response rate and 17.8 months overall survival to date.

Positive

• Insiders purchased 182,445 shares Nov 21–28, 2025
• Chairman/CEO bought 94,300 shares at $1.08 average
• Directors bought 88,145 shares at $1.04 average
• Phase 2 THIO-101: 38% response rate reported

Negative

• Phase 2 THIO-101 data described as "to date" (interim)

Argus Dec 1 session

+1.69% close to close Open Argus

Details

News Market Reaction – MAIA

On Dec 1, the day this news came out, MAIA closed 1.69% above the previous close.

Data tracked by StockTitan Argus for the Dec 1 session.

Market Context

This announcement details open-market purchases totaling 182,445 shares by MAIA’s CEO and directors ...

Analysis

This announcement details open-market purchases totaling 182,445 shares by MAIA’s CEO and directors at an average of $1.06, alongside reaffirmation of Phase 2 THIO-101 data showing a 38% response rate and 17.8 months overall survival in NSCLC. In recent months, MAIA has repeatedly highlighted ateganosine’s progress and initiated pivotal development. Investors may track future clinical readouts, additional insider activity, and regulatory milestones to contextualize these developments.

Key Figures

Insider purchases: 182,445 shares Average purchase price: $1.06 per share CEO purchases: 94,300 shares at $1.08 +5 more

Insider purchases

182,445 shares

CEO and directors’ open-market buys between Nov 21–28, 2025

Average purchase price

$1.06 per share

Blended average for 182,445 insider-purchased shares

CEO purchases

94,300 shares at $1.08

Vlad Vitoc’s open-market buys Nov 21–28, 2025

Other directors’ purchases

88,145 shares at $1.04

Combined open-market buys by Cristian Luput and Stan V. Smith

Response rate

38%

Phase 2 THIO-101 trial in NSCLC to date

Overall survival

17.8 months

Observed OS in Phase 2 THIO-101 clinical trial

Pre-news price

$1.64

Price with <b>2.22%</b> 24h change before this article

52-week range

$0.87–$2.74

Stock trading between 52-week low and high levels

Historical Context

5 past events · Latest: Dec 10

5 events

1. Dec 10

   Market opportunity update

   24h Move

   +2.2%

   Outlined $50B immunotherapy market and Phase 3 THIO-104 initiation for ateganosine.

2. Dec 01

   Insider share purchases

   24h Move

   +1.7%

   CEO and directors bought 182,445 shares and reiterated Phase 2 THIO-101 results.

3. Nov 21

   SITC 2025 clinical data

   24h Move

   +4.7%

   Reported THIO-101 expansion enrollment and 17.8-month OS plus Phase 3 screening start.

4. Nov 20

   Conference presentation

   24h Move

   -5.3%

   CEO presented telomere-targeting efficacy and 38% response rate vs ~6% current options.

5. Oct 27

   Trial in Progress poster

   24h Move

   +4.9%

   Reported first five Part C THIO-101 patients and a safety profile consistent with earlier parts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunotherapies, Phase 2, clinical trial, overall survival, +1 more

5 terms

immunotherapies medical

"a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

Phase 2 medical

"With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101 clinical trial"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical trial medical

"17.8 months overall survival in our Phase 2 THIO-101 clinical trial to date"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

overall survival medical

"With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

non-small cell lung cancer medical

"patients diagnosed with non-small cell lung cancer and become a new standard of care"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06.

Vlad Vitoc, M.D., Chairman and CEO of MAIA, purchased 94,300 shares between November 21 and 28, 2025, at an average price of $1.08 per share. Other board members, Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares in the open market at an average price of $1.04 per share.

“Along with my fellow MAIA Board members, we are pleased to report that we recently acquired shares of MAIA in the open market, reflecting our confidence in ateganosine’s ongoing clinical development,” said Dr. Vitoc. “With 38% response rates and 17.8 months overall survival in our Phase 2 THIO-101 clinical trial to date, we believe in ateganosine’s potential to improve the lives of patients diagnosed with non-small cell lung cancer and become a new standard of care.”

“I firmly believe MAIA’s cancer-therapy platform can redefine the landscape of cancer research and treatment,” said Mr. Luput. “As a longtime investor, I believe the company’s strategic focus and scientific momentum position it to deliver significant value for shareholders in the years ahead,” added Mr. Smith.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MAIA (MAIA) shares did the CEO and directors buy in November 2025?

They purchased approximately 182,445 shares in open-market trades between November 21–28, 2025.

What average price did MAIA insiders pay for the November 2025 purchases?

The combined average price was $1.06 per share; CEO average was $1.08, directors' average $1.04.

What clinical results did MAIA cite for ateganosine in the Phase 2 THIO-101 trial?

MAIA reported a 38% response rate and 17.8 months overall survival in the Phase 2 THIO-101 trial to date.

When were the MAIA insider purchases disclosed?

The company announced the open-market purchases on December 1, 2025 covering trades made November 21–28, 2025.

Do the MAIA insider purchases guarantee clinical or commercial success for ateganosine?

No; the purchases reflect insider purchases and confidence but do not guarantee regulatory approval or commercial success.